High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality

Current Cardiovascular Risk Reports

Volumn 4, Issue 1, 2010, Pages 1-8

  Gordon, Scott ^a   Durairaj, Anita ^a   Lu, Jason L ^b   Davidson, W Sean ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Apolipoprotein; Cardiovascular disease; High density lipoprotein; Lipoprotein; Mass spectrometry; Protein; Proteomics; Reverse cholesterol transport

Indexed keywords

EID: 84873524007     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-009-0069-9     Document Type: Article

References (45)

1. Adorni MP, Zimetti F, Billheimer JT, et al.: The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007, 48: 2453-2462.
2. Gu X, Trigatti B, Xu S, et al.: The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J Biol Chem 1998, 273: 26338-26348.
3. Moore RE, Navab M, Millar JS, et al.: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005, 97: 763-771.
4. Navab M, Hama SY, Anantharamaiah GM, et al.: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3. J Lipid Res 2000, 41: 1495-1508.
5. Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121: 1-12.
6. Navab M, Imes SS, Hama SY, et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88: 2039-2046.
7. Puranik R, Bao S, Nobecourt E, et al.: Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008, 196: 240-247.
8. Rye KA, Bursill CA, Lambert G, et al.: The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009, 50(Suppl): S195-S200.
9. Concha MI, Smith VJ, Castro K, et al.: Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio. Eur J Biochem 2004, 271: 2984-2990.
10. Cruz D, Watson AD, Miller CS, et al.: Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008, 118: 2917-2928.
11. • Heinecke JW: The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J Lipid Res 2009, 50(Suppl): S167-S171. This excellent summary of HDL proteomics focuses on the work of the Heinecke laboratory.
12. • Hoofnagle AN, Heinecke JW: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 2009, 50: 1967-1975. This article presents another good review of HDL proteomics.
13. Reilly MP, Tall AR: HDL proteomics: pot of gold or Pandora's box? J Clin Invest 2007, 117: 595-598.
14. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23: 1881-1888.
15. Cheung MC, Albers JJ: Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984, 259: 12201-12209.
16. Asztalos BF, Sloop CH, Wong L, Roheim PS: Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993, 1169: 291-300.
17. Warnick GR, Nauck M, Rifai N: Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001, 47: 1579-1596.
18. Duong PT, Weibel GL, Lund-Katz S, et al.: Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 2008, 49: 1006-1014.
19. Haginaka J, Yamaguchi Y, Kunitomo M: Anion-exchange high-performance liquid chromatography assays of plasma lipoproteins and modified low-density lipoproteins using a ProtEx-DEAE column. J Chromatogr B Biomed Sci Appl 2001, 751: 161-167.
20. van't Hooft F, Havel RJ: Metabolism of apolipoprotein E in plasma high density lipoproteins from normal and cholesterol-fed rats. J Biol Chem 1982, 257: 10996-11001.
21. • Stahlman M, Davidsson P, Kanmert I, et al.: Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 2008, 49: 481-490. This article presents a comparison of different methods for floating lipoproteins during density ultracentrifugation that shows the potential for artifacts in the KBr procedure.
22. Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5: 551-565.
23. Santos RD, Schaefer EJ, Asztalos BF, et al.: Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res 2008, 49: 349-357.
24. Movva R, Rader DJ: Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54: 788-800.
25. Davidson WS, Jonas A, Clayton DF, George JM: Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998, 273: 9443-9449.
26. Canas B, Lopez-Ferrer D, Ramos-Fernandez A, et al.: Mass spectrometry technologies for proteomics. Brief Funct Genomic Proteomic 2006, 4: 295-320.
27. Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5: 1431-1445.
28. Subramaniyam D, Glader P, von Wachenfeldt K, et al.: C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int J Biochem Cell Biol 2006, 38: 563-575.
29. Heller M, Stalder D, Schlappritzi E, et al.: A. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 2005, 5: 2619-2630.
30. Rezaee F, Casetta B, Levels JH, et al.: Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6: 721-730.
31. Hortin GL, Shen RF, Martin BM, Remaley AT: Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun 2006, 340: 909-915.
32. 3from CAD patients was selectively enriched in apoE and other proteins that may play a role in macrophage biology, lipid metabolism, and the inflammatory response.
33. •• Green PS, Vaisar T, Pennathur S, et al.: Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118: 1259-1267. This is the first study to utilize HDL proteomics as a measure of the efficacy of lipid-lowering therapies.
34. •• Davidson WS, Silva RA, Chantepie S, et al.: Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29: 870-876. This study mapped the HDL proteome across five density subfractions indicating clearly distinct protein profiles. This study also associated specific apolipoproteins with antioxidative function.
35. Boyle KE, Phillips MC, Lund-Katz S: Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta 1999, 1430: 302-312.
36. Qiu X, Mistry A, Ammirati MJ, et al.: Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007, 14: 106-113.
37. Asztalos BF, Schaefer EJ: High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91: 12E-17E.
38. Jonas A: Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta 1991, 1084: 205-220.
39. Wang X, Driscoll DM, Morton RE: Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999, 274: 1814-1820.
40. Jahangiri A, Rader DJ, Marchadier D, et al.: Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 2005, 46: 896-903.
41. Rifkin MR: Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci U S A 1978, 75: 3450-3454.
42. Nielsen MJ, Nielsen LB, Moestrup SK: High-density lipoprotein and innate immunity. Future Lipidol 2006, 1: 729-734.
43. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL: Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 2005, 280: 32578-32585.
44. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101: 207-213.
45. Ansell BJ, Navab M, Hama S, et al.: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108: 2751-2756.